Source: OncLive, June 2025
Jason Luke, MD, associate director for clinical research and director of the Immunotherapy and Drug Development Center at Hillman Cancer Center, University of Pittsburgh, discussed the design and potential clinical effects of the phase 3 SUPRAME trial (NCT06743126), which is evaluating the efficacy of IMA203, a T-cell receptor–transduced T-cell therapy (TCR-T), vs investigator’s choice of standard therapy in patients with previously treated advanced cutaneous melanoma.
Luke explained that SUPRAME represents the first randomized phase 3 trial in solid tumors directly comparing a TCR-T-cell therapy with conventional systemic treatment in a refractory setting. In the trial, patients are randomly assigned to receive either IMA203 or the treating physician’s choice of standard therapy, Luke explains.